Brief Report: Intranasal Ketamine in Adolescents and Young Adults with Autism Spectrum Disorder—Initial Results of a Randomized, Controlled, Crossover, Pilot Study
| Autor: | Debra L. Reisinger, Lauren M. Schmitt, Paul S. Horn, Rebecca C. Shaffer, Craig A. Erickson, Kaela O'Brien, Logan K. Wink, Ernest V. Pedapati, Kelli R Dominick |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Pediatrics Neurology 05 social sciences medicine.disease Placebo Clinical trial 03 medical and health sciences 0302 clinical medicine Autism spectrum disorder Developmental and Educational Psychology medicine Intranasal Ketamine Autism 0501 psychology and cognitive sciences Ketamine Psychology Adverse effect 030217 neurology & neurosurgery 050104 developmental & child psychology medicine.drug |
| Zdroj: | Journal of Autism and Developmental Disorders. 51:1392-1399 |
| ISSN: | 1573-3432 0162-3257 |
| DOI: | 10.1007/s10803-020-04542-z |
| Popis: | Dysregulation of glutamate neurotransmission plays a critical role in autism spectrum disorder (ASD) pathophysiology and is a primary target for core deficit research treatment trials. The mechanism of action of ketamine has striking overlap with the theory of ASD as a disorder of synaptic communication and neuronal networks. This two-dose, double-blind, placebo controlled, cross-over pilot trial of intranasal (IN) ketamine targeting core social impairment included individuals with ASD (N = 21) between 14 and 29 years. Participants were randomized to received two doses of IN ketamine (30 and 50 mg) and two doses of matching placebo. No significant impact was noted on the Aberrant Behavior Checklist Social Withdraw subscale. The IN ketamine was well tolerated, with only transient mild adverse effects. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink